Skip to main content
  1. Home

Submission Tool and Repository Measure Database

As the Centers for Medicare & Medicaid Services (CMS) consensus-based entity (CBE), Battelle Memorial Institute (Battelle) discloses complete information (e.g., full measure specifications, coding logic, algorithms) regarding each measure to the public for the purpose of evaluating, analyzing, or displaying of each measure for endorsement consideration. If an interested party wishes to attain complete measure information for the use and/or implementation of a measure, the interested party should contact the measure steward. Contact information for the measure steward can be found under the “Point of Contact” section of the respective." measure page within the Submission Tool and Repository (STAR). Battelle is not responsible for, nor is privy to the measure use agreements that may be established between a measure steward and an interested party.
No Filters Selected
          For the filters below, open and close each one at a time for the best experience
          CBE ID Title Steward Endorsement Cycle Status Date of Last Endorsement Decision
          1662 Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Endorsed with Conditions
          0384 Oncology: Medical and Radiation – Pain Intensity Quantified Endorsed with Conditions
          0384e Oncology: Medical and Radiation – Pain Intensity Quantified Endorsed with Conditions
          0383 Oncology: Medical and Radiation – Plan of Care for Pain Endorsed
          0694 Hospital Risk-Standardized Complication Rate Following Implantation of Implantable Cardioverter-Defibrillator (ICD) Endorsement Removed
          0695 Hospital 30-Day Risk-Standardized Readmission Rates following Percutaneous Coronary Intervention (PCI) Endorsement Removed
          0221 Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection American College of Surgeons Endorsement Removed
          0559 Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0 or stage IB - III hormone receptor negative breast cancer American College of Surgeons Endorsement Removed
          0534 Hospital specific risk-adjusted measure of mortality or one or more major complications within 30 days of a lower extremity bypass (LEB). American College of Surgeons Endorsement Removed
          0223 Adjuvant chemotherapy is recommended, or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer American College of Surgeons Endorsed
          Displaying 1 - 10 of 1215

          The Submission Tool and Repository (STAR) is a measure database of quality performance measures that have been submitted to the previous consensus-based entity for endorsement review. The STAR database will be updated regularly as new and maintenance measures are submitted to the Partnership for Quality Measurement for endorsement review. Battelle will be providing additional enhancements to the STAR database as measure information is submitted in order to better support the accessibility of timely and accurate measure information for all interested parties.